Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) Target Price at $24.00

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $22.50.

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Lake Street Capital raised their price target on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Bank of America lifted their price objective on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Needham & Company LLC decreased their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Apis Capital Advisors LLC raised its stake in Cellebrite DI by 34.4% during the 4th quarter. Apis Capital Advisors LLC now owns 820,000 shares of the company’s stock valued at $14,785,000 after purchasing an additional 210,000 shares during the last quarter. Armistice Capital LLC acquired a new stake in Cellebrite DI in the 4th quarter worth $302,000. Praesidium Investment Management Company LLC increased its holdings in shares of Cellebrite DI by 339.9% during the 4th quarter. Praesidium Investment Management Company LLC now owns 1,185,274 shares of the company’s stock worth $21,370,000 after purchasing an additional 915,821 shares during the period. Pertento Partners LLP raised its position in shares of Cellebrite DI by 28.2% during the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after buying an additional 1,311,109 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of Cellebrite DI during the fourth quarter valued at about $972,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

CLBT opened at $14.30 on Wednesday. The company has a market cap of $3.42 billion, a PE ratio of 46.13, a price-to-earnings-growth ratio of 2.15 and a beta of 1.28. The stock has a 50-day moving average of $16.90 and a 200-day moving average of $17.03. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.14. The business had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm’s revenue was up 28.8% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS. On average, research analysts predict that Cellebrite DI will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.